Triptolide sensitizes breast cancer cells to Doxorubicin through the DNA damage response inhibition

2018 ◽  
Vol 57 (6) ◽  
pp. 807-814 ◽  
Author(s):  
Yu Deng ◽  
Fulun Li ◽  
Pinglin He ◽  
Yafei Yang ◽  
Jin Yang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Response Inhibition ◽  
Breast Cancer Cells ◽  
Damage Response

scholarly journals Adaptation to chronic exposure to sepantronium bromide (YM155), a prototypical survivin suppressant is due to persistent DNA damage-response in breast cancer cells

Oncotarget ◽  
2018 ◽  
Vol 9 (71) ◽  
pp. 33589-33600 ◽  
Author(s):  
Tasaduq H. Wani ◽  
Sreeraj Surendran ◽  
Vishnu S. Mishra ◽  
Jaya Chaturvedi ◽  
Goutam Chowdhury ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Chronic Exposure ◽  
Breast Cancer Cells ◽  
Damage Response ◽  
Sepantronium Bromide

scholarly journals RAD50 targeting impairs DNA damage response and sensitizes human breast cancer cells to cisplatin therapy

2014 ◽  
Vol 15 (6) ◽  
pp. 777-788 ◽  
Author(s):  
Ali Flores-Pérez ◽  
Lourdes E Rafaelli ◽  
Nayeli Ramírez-Torres ◽  
Elena Aréchaga-Ocampo ◽  
Sara Frías ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Damage ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Human Breast Cancer ◽  
Breast Cancer Cells ◽  
Human Breast Cancer Cells ◽  
Human Breast ◽  
Damage Response ◽  
Cisplatin Therapy

RO3280: A Novel PLK1 Inhibitor, Suppressed the Proliferation of MCF-7 Breast Cancer Cells Through the Induction of Cell Cycle Arrest at G2/M Point

2019 ◽  
Vol 19 (15) ◽  
pp. 1846-1854 ◽  
Author(s):  
Mustafa Ergul ◽  
Filiz Bakar-Ates
Keyword(s):  
Breast Cancer ◽  
Cell Cycle ◽  
Dna Damage ◽  
Cell Cycle Arrest ◽  
Cancer Cells ◽  
Dna Damage Response ◽  
Breast Cancer Cells ◽  
Cycle Arrest ◽  
Damage Response ◽  
Mcf 7

Background: As a member of serine/threonine-protein kinase, Polo‐like kinase 1 (PLK1) plays crucial roles during mitosis and also contributes to DNA damage response and repair. PLK1 is aberrantly expressed in many types of tumor cells and increased levels of PLK1 is closely related to tumorigenesis and poor clinical outcomes. Therefore, PLK1 is accepted as one of the potential targets for the discovery of novel anticancer agents. The objective of this study was to assess the cytotoxic effects of a novel PLK1 inhibitor, RO3280, against MCF-7, human breast cancer cells; HepG2, human hepatocellular carcinoma cells; and PC3, human prostate cancer cells, as well as non-cancerous L929 fibroblast cells. Methods: Antiproliferative activity of RO3280 was examined using the XTT assay. Flow cytometry assay was performed to evaluate cell cycle distribution, apoptosis, multicaspase activity, mitochondrial membrane potential, and DNA damage response. We also examined apoptosis with fluorescence imaging studies. Results: According to the results of XTT assay, although RO3280 displayed potent cytotoxicity in all treated cancer cells, the most sensitive cell line was identified as MCF-7 cells that were selected for further studies. The compound induced a cell cycle arrest in MCF-7 cells at G2/M phase and significantly induced apoptosis, multicaspase activity, DNA damage response, and decreased mitochondrial membrane potential of MCF-7 cells. Conclusion: Overall, RO3280 induces anticancer effects promoted mainly by DNA damage, cell cycle arrest, and apoptosis in breast cancer cells. Further studies are needed to assess its usability as an anticancer agent with specific cancer types.

Sign in / Sign up

Export Citation Format

Share Document